Absci (ABSI) Operating Income Growth (3y) (2023 - 2026)

Absci (ABSI) Operating Income Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (3y) (Qtr)
1 Oculis Holding AG 67,102.16 Bn 67,101.87 Bn - 16.96%
2 Nanobiotix 1,913.50 Bn 1,913.44 Bn - -
3 Akari Therapeutics 959.56 Bn 959.56 Bn - -
4 BeOne Medicines 472.39 Bn 467.60 Bn 1.35 Bn 38.78%
5 Vertex Pharmaceuticals 122.08 Bn 114.83 Bn 2.59 Bn 13.47%
6 Regeneron Pharmaceuticals 69.98 Bn 61.22 Bn 3.31 Bn -12.10%
7 Belite Bio 62.34 Bn 62.34 Bn - -
8 Argenx Se 55.97 Bn 50.78 Bn 1.41 Bn 69.02%
9 Alnylam Pharmaceuticals 37.47 Bn 34.46 Bn 959.66 Mn 55.96%
10 Absci 1.18 Bn 1.06 Bn - -8.00%

Historic Data

Download Data
DateValue
Mar 31, 2026 -8.00%
Dec 31, 2025 -13.75%
Sep 30, 2025 -2.54%
Jun 30, 2025 -2.81%
Mar 31, 2025 1.26%
Dec 31, 2024 -4.28%
Sep 30, 2024 -10.98%
Jun 30, 2024 -16.98%
Mar 31, 2024 -28.22%
Dec 31, 2023 -74.79%
Sep 30, 2023 -90.63%
Jun 30, 2023 -148.13%